Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2013371.pdf
Reference33 articles.
1. Assouline S, Buccheri V, Delmer A, Doelken G, Gaidano G, McIntyre C, Brewster M, Hourcade-Potelleret F, Sayyed P, Badoux X (2012) Subcutaneous rituximab in combination with fludarabine and cyclophosphamide for patients with CLL: initial results of a phase Ib study (SAWYER [BO25341]) show non-inferior pharmacokinetics and comparable safety to that of intravenous rituximab. Blood 120: Abstract 1637.
2. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114: 230–241.
3. Chan AL, Leung HW, Lu CL, Lin SJ (2009) Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review. Ann Pharmacother 43: 296–303.
4. Davies A, Merli F, Mihaljevik B, Siritanaratkul N, Solal-Céligny P, Boehnke A, Berge C, McIntyre C, Barrett M, Macdonald D (2012) Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the phase III SABRINA study (BO22334). Blood 120: Abstract 1629.
5. Del Nagro CJ, Mao CP, Brovarney M (2010) Comparison of B cell depletion mediated by intravenous (IV) Rituxan and Rituxan given subcutaneous (SC) in cynomolgus monkeys. Blood 116: Abstract 3980.
Cited by 119 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reversible protein complexes: Advancing subcutaneous delivery with controlled and sustained release of high concentration biologics;Journal of Drug Delivery Science and Technology;2024-10
2. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10
3. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20
4. Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation;Bioconjugate Chemistry;2024-05-24
5. Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20;Clinical and Translational Science;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3